

POSTER PRESENTATION

Open Access

Efficiency of different airborne disinfection products for reducing the risk of *Aspergillus fumigatus* infection from hospital false ceiling exposure

S Loeffert^{1*}, M-P Gustin², P Cassier³, P Bouche³, C Lion³, M Massacrier³, M Perraud³, P Vanhems¹

From 3rd International Conference on Prevention and Infection Control (ICPIC 2015) Geneva, Switzerland. 16-19 June 2015

Introduction

In hospital, false ceilings are a source of *Aspergillus*. A huge amount of spores may be suspended specially during their demolition near immunocompromised patients who are at risk to develop severe invasive aspergillosis (IA). Airway disinfection allows the no directed spraying of a disinfectant on surfaces contained into a determined volume.

Objectives

The aim of this study was to evaluate the antifungal efficacy of a new airborne disinfectant (AD) on hospital false ceilings compared to another AD usually used, before major deconstruction work.

Methods

The antifungal activity of the two AD was assessed in 4 rooms of an hospital ward in a building intended to be demolished. The two AD tested were based on hydroxyacetic acid for AD#1 and on peracetic acid and H₂O₂ for AD#2. Each AD was randomly applied in rooms as recommended by the manufacturer with comparable trial conditions (location and contact time with AD). Fungal contamination (F_c) of the top of false ceiling slabs was assessed using moistened swabs before and after application of the AD. The environmental contamination was then extracted and inoculated on YGC agar. On each plate *A. fumigatus* and *A. niger* were counted. Contamination rates (C_R) were compared after logarithmic transformation by nonparametric tests.

Results

A total of, 11 false ceiling tiles were sampled before and after AD in each room (a total of 88 tiles). Before disinfection, C_R of rooms were not different. For AD#1 the C_R for *A. fumigatus* was 1.86 before AD and 1.59 log₁₀ after ($p=0.80$), for *A. niger* the C_R was 0.45 before and 0.24 log₁₀ after ($p=0.24$). For AD#2 the C_R for *A. fumigatus* was of 1.69 before AD and 0.80 log₁₀ after ($p=0.01$), for *A. niger* the C_R was of 0.60 before AD and 0 log₁₀ after ($p=0.001$). Concerning AD#1, the C_R reduction was then 0.89 and 0.60 log₁₀ for *A. fumigatus* and *A. niger* respectively.

Conclusion

The new AD#2 was the most efficient to reduce F_c of hospital false ceiling slabs before demolition. These results will be of major help to choose the best AD procedure for improving the control of *A. fumigatus* risk and ultimately prevent IA in our patients during construction works of our hospital.

Disclosure of interest

S. Loeffert Grant/Research support from: ANIOS Laboratories. The authors thank ANIOS Laboratories for their participation in this study by providing free of charge products. Anios was not involved in the study design, analysis results or discussion., M.-P. Gustin: None declared, P. Cassier: None declared, P. Bouche: None declared, C. Lion: None declared, M. Massacrier: None declared, M. Perraud: None declared, P. Vanhems: None declared.

¹UMR CNRS 5558 Biometry and Evolutive Biology Laboratory, Claude Bernard University, Lyon, France

Full list of author information is available at the end of the article

Authors' details

¹UMR CNRS 5558 Biometry and Evolutive Biology Laboratory, Claude Bernard 1 University, Lyon, France. ²Institut of Pharmaceutical Sciences and Biology (ISPB), Claude Bernard 1 University, Lyon, France. ³Environmental Safety and Biology Laboratory , Edouard Herriot Hospital, Lyon, France.

Published: 16 June 2015

doi:10.1186/2047-2994-4-S1-P50

Cite this article as: Loeffert *et al.*: Efficiency of different airborne disinfection products for reducing the risk of *Aspergillus fumigatus* infection from hospital false ceiling exposure. *Antimicrobial Resistance and Infection Control* 2015 **4**(Suppl 1):P50.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

